The orthostatic hypotension drugs market value is set to grow by $571.76M 2021 to 2026, progressing at a CAGR of 9.06% as per the latest market report by Technavio. 42% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for the orthostatic hypotension drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW. The high per capita pharmaceutical expenditure will facilitate the orthostatic hypotension drugs market growth in North America over the forecast period.
The market is driven by factors such as the increasing prevalence ofOH in the geriatric population, the increasing prevalence of chronic diseases associated with a high risk of OH, and the high market growth opportunities for OH drugs in emerging countries. However, the low diagnosis rate of OH is hindering market growth. The holistic analysis of the drivers & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge.
The orthostatic hypotension drugs market is fragmented and the vendors are deploying growth strategies such as expanding their product portfolios by investing in R and D to compete in the market. The orthostatic hypotension drugs market report includes information on the product launches, sustainability, and prospects of many leading vendors.